심정지 치료 시장 : 치료 유형, 연령층, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Cardiac Arrest Treatment Market is projected to grow by USD 48.53 billion at a CAGR of 9.54% by 2032.

Cardiac arrest treatment is a time-critical continuum that spans early recognition, emergency medical dispatch, high-quality cardiopulmonary resuscitation, rapid defibrillation, advanced life support, post-arrest intensive care, and rehabilitation. The clinical and commercial priority is clear: survival declines sharply when CPR and defibrillation are delayed, while bystander CPR and public-access automated external defibrillators improve the probability of neurologically favorable survival.

The market is shaped by demand for automated external defibrillators, manual defibrillators, CPR feedback devices, resuscitation drugs, targeted temperature management systems, extracorporeal cardiopulmonary resuscitation, and integrated emergency medical services workflows. Evidence from the American Heart Association, International Liaison Committee on Resuscitation, European Resuscitation Council, World Health Organization, and national cardiac arrest registries supports a consistent theme: systems of care, not single products, drive outcomes.

Transformative Shifts in the Cardiac Arrest Treatment Landscape

The cardiac arrest treatment landscape is shifting from episodic emergency response toward integrated, data-enabled resuscitation systems. Public-access defibrillation programs, dispatcher-assisted CPR, mobile responder activation, school and workplace CPR training, and real-time CPR quality feedback are becoming central to community survival strategies. Hospitals are also standardizing post-cardiac arrest pathways that include coronary evaluation, hemodynamic optimization, temperature control where clinically appropriate, seizure management, ventilation optimization, rehabilitation planning, and structured neuroprognostication.

Medical technology suppliers are responding with connected AED fleets, cloud-based device readiness monitoring, waveform analytics, and interoperable documentation tools. Health systems and EMS agencies are prioritizing measurable performance indicators, including call-to-compression time, collapse-to-shock time, chest compression fraction, return of spontaneous circulation, survival to discharge, and cerebral performance outcomes. This transformation favors organizations that can combine clinically validated devices with training, service support, analytics, and compliance-ready data infrastructure.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing cardiac arrest treatment across prevention, detection, response, and post-arrest care. AI-enabled emergency call analysis can support dispatchers in recognizing suspected cardiac arrest, while geospatial analytics can optimize AED placement based on historical incident density, population flow, and response-time gaps. Wearables and remote monitoring platforms are also expanding the opportunity for earlier recognition of arrhythmia risk, particularly in high-risk cardiovascular populations.

In clinical operations, AI can help analyze CPR quality, predict deterioration in monitored patients, support intensive care risk stratification, and improve resource coordination. However, adoption depends on validated performance, bias assessment, explainability, cybersecurity, privacy protection, and regulatory oversight. The strongest near-term value will come from human-in-the-loop tools that reduce delays, strengthen protocol adherence, and generate auditable quality improvement data.

Key Regional Insights

North America remains a leading region for cardiac arrest treatment adoption due to mature EMS systems, widespread AED deployment, active registry participation, and strong guideline implementation. The United States reports more than 356,000 out-of-hospital cardiac arrests annually, according to the American Heart Association, making rapid CPR and defibrillation a major public health priority. Canada adds strong provincial cardiac arrest networks, public-access defibrillation programs, and community responder initiatives.

Europe benefits from coordinated resuscitation guidelines, national and regional registries, and public-access defibrillation initiatives, although survival varies by country, EMS configuration, and local response capacity. The European Union is advancing emergency health digitization and medical device oversight, while the United Kingdom, Germany, France, Italy, Spain, and Russia continue to strengthen EMS modernization, hospital-based post-arrest care, and public education for early CPR.

Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and ASEAN countries increase emergency care investment, AED availability, and CPR education. Japan and Australia have well-established community defibrillation and OHCA reporting models, while India and several Southeast Asian countries present large unmet needs due to variable ambulance access, limited bystander CPR penetration, and uneven public AED coverage.

Latin America, the Middle East, and Africa show rising demand for defibrillators, emergency training, and hospital resuscitation capacity. Brazil and Mexico are regional anchors in Latin America, GCC countries are investing in smart emergency response infrastructure and ambulance connectivity, and African markets require scalable, lower-cost solutions for EMS coverage, AED access, maintenance reliability, and workforce training.

Key Group Insights

ASEAN presents a major opportunity for cardiac arrest treatment as urbanization, cardiovascular disease burden, and emergency care investment rise together. Market development is strongest where governments support CPR education, ambulance modernization, and public AED placement in airports, malls, transport hubs, schools, and workplaces. Interoperable, low-maintenance AED programs are especially relevant for humid, high-traffic environments and for systems with mixed public and private emergency response models.

The GCC is advancing premium emergency care through hospital investment, digital health strategies, and smart-city emergency response systems. Saudi Arabia, the United Arab Emirates, Qatar, and neighboring markets are prioritizing rapid response, connected ambulance systems, public-venue preparedness, and emergency readiness for large-scale events, supporting demand for reliable defibrillation, simulation-based training, and integrated dispatch workflows.

The European Union benefits from guideline harmonization, medical device regulation, and cross-border evidence generation, supporting demand for clinically validated defibrillation, CPR feedback, and post-arrest care technologies. BRICS markets represent scale and system diversity, with China and India driving broad access needs, Brazil and South Africa expanding public health infrastructure, and Russia maintaining strong hospital-based care networks despite regional procurement complexity.

G7 markets remain innovation leaders due to advanced EMS systems, higher healthcare spending, established clinical registries, and early adoption of connected medical devices. NATO members add demand linked to military medical readiness, mass-casualty preparedness, disaster response, and resilient emergency response networks, making ruggedized defibrillation, training systems, and deployable resuscitation solutions strategically important.

Key Country Insights

The United States leads in cardiac arrest treatment innovation, registry-driven quality improvement, and connected AED adoption, supported by evidence-based resuscitation guidelines and a large EMS base. Canada emphasizes provincial systems of care, community CPR, and public-access defibrillation. Mexico and Brazil are expanding emergency care capacity, with demand shaped by urban EMS gaps, private hospital investment, and high cardiovascular disease prevalence.

In Europe, the United Kingdom has strong resuscitation council guidance, ambulance performance monitoring, and public AED campaigns, while Germany combines advanced ambulance physician systems with high hospital capability. France emphasizes SAMU-based emergency coordination, Italy and Spain continue to expand public defibrillation access and CPR awareness, and Russia maintains significant hospital infrastructure but faces uneven regional deployment and procurement variation.

China is scaling emergency medicine capacity, AED installations, and CPR awareness across major cities. India has substantial unmet need due to high cardiovascular burden, variable ambulance coverage, and low community CPR penetration, creating demand for affordable AEDs, training, and hospital resuscitation protocols. Japan benefits from one of the world's most established public-access defibrillation networks and extensive out-of-hospital cardiac arrest registry evidence. Australia has strong EMS performance, community responder models, and public health programs supporting early defibrillation. South Korea continues to strengthen dispatcher-assisted CPR, public AED programs, and national registry-based improvement.

Across all countries, the most defensible opportunities align with guideline-concordant care, device readiness, user-friendly AED design, training retention, EMS integration, and measurable neurological survival outcomes rather than equipment procurement alone.

Actionable Recommendations for Industry Leaders

Industry leaders should position cardiac arrest treatment offerings as outcome-oriented systems rather than standalone devices. Priority actions include expanding public-access AED coverage in high-risk and high-traffic locations, integrating device readiness monitoring, supporting dispatcher-assisted CPR, and providing recurring training that uses feedback-enabled manikins and scenario-based learning.

Medical technology companies should invest in interoperability with EMS records, hospital electronic health records, and quality registries. Providers should track survival to discharge and neurological outcomes, not only return of spontaneous circulation. Public agencies and buyers should use evidence-based placement models, maintenance compliance, and response-time analytics to guide procurement. AI solutions should be deployed only with clinical validation, privacy safeguards, bias monitoring, cybersecurity controls, and clear accountability for human oversight.

Research Methodology

This executive summary is developed through a structured review of verified secondary evidence, including resuscitation guidelines, national and regional cardiac arrest registries, peer-reviewed clinical literature, regulatory materials, public health publications, and emergency medical services performance frameworks. Core sources include the American Heart Association, International Liaison Committee on Resuscitation, European Resuscitation Council, World Health Organization, and country-level health authorities where available.

The methodology prioritizes data consistency, clinical relevance, and market applicability. Insights are triangulated across epidemiology, treatment pathways, device adoption, reimbursement context, regional healthcare infrastructure, emergency response maturity, regulatory direction, and technology readiness. Forward-looking statements are limited to observable adoption patterns, documented policy priorities, and verified investment themes.

Conclusion

Cardiac arrest treatment is evolving into a connected ecosystem built around early recognition, immediate CPR, rapid defibrillation, advanced resuscitation, and evidence-based post-arrest care. The strongest market opportunities are tied to measurable survival improvement, operational readiness, equitable access, and scalable training.

Organizations that combine clinically validated technologies with analytics, EMS integration, reliable AED maintenance, and rigorous quality improvement will be best positioned to lead. As AI and connected devices mature, success will depend on trustworthy implementation that shortens time to treatment, supports clinical decision-making, and improves neurologically meaningful survival.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiac Arrest Treatment Market, by Treatment Type

• 7.1. Cpr Devices
  • 7.1.1. Load Distributing Band Device
  • 7.1.2. Piston Driven Device
  • 7.1.3. Pneumatic Vest Device
• 7.2. Defibrillator Devices
  • 7.2.1. Automated External Defibrillator
  • 7.2.2. Implantable Cardioverter Defibrillator
  • 7.2.3. Wearable Cardioverter Defibrillator
• 7.3. Drug Therapies
• 7.4. Hypothermia Systems
• 7.5. Monitoring Systems
  • 7.5.1. Capnography Systems
  • 7.5.2. Ecg Monitors

8. Cardiac Arrest Treatment Market, by Age Group

• 8.1. Adult
• 8.2. Geriatric
• 8.3. Pediatric

9. Cardiac Arrest Treatment Market, by Distribution Channel

• 9.1. Offline
• 9.2. Online

10. Cardiac Arrest Treatment Market, by End User

• 10.1. Ambulatory Care Center
• 10.2. Emergency Medical Services
• 10.3. Home Care
• 10.4. Hospital

11. Cardiac Arrest Treatment Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Cardiac Arrest Treatment Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Cardiac Arrest Treatment Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. ACON Laboratories Inc.
• 15.3. Becton, Dickinson and Company
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. bioMerieux S.A.
• 15.6. Boston Scientific Corporation
• 15.7. Cipla Limited
• 15.8. Danaher Corporation
• 15.9. F. Hoffmann-La Roche Ltd.
• 15.10. Fukuda Denshi Co., Ltd.
• 15.11. Jant Pharmacal Corporation
• 15.12. Johari Digital India Limited by Syrma SGS
• 15.13. Koninklijke Philips N.V.
• 15.14. LifeSign LLC
• 15.15. LifeSync
• 15.16. Luminex Corporation by DiaSorin S.p.A.
• 15.17. Mitsubishi Chemical Group Corporation
• 15.18. Nexus Dx, Inc
• 15.19. Nihon Kohden Corporation
• 15.20. Quidel Corporation
• 15.21. Schiller AG
• 15.22. Shenzhen EDAN Instrument Co., Ltd.
• 15.23. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 15.24. Siemens Healthineers AG
• 15.25. Spectral Diagnostics Inc.
• 15.26. Trinity Biotech PLC